



CTSU ECOG E5508 Study for Non-Small Cell Lung Cancer



Thank you for participating in this study!

We want to thank you for participating in our study of Non-Small Cell Lung Cancer (NSCLC) treatment. We cannot do important research like this without you!

What was the Study?

This study wanted to find out the best maintenance regimen for patients with advanced stage NSCLC. Maintenance therapy is usually given after 4 cycles of standard chemotherapy (1 cycle = 21 days) to keep the disease under control longer. The Cancer Trials Support Unit (CTSU) is a service of the National Cancer Institute (NCI) designed to facilitate access to NCI-funded clinical trials. Along with other member sites, Duke's study team ran this study that tested three treatments of NSCLC maintenance therapies and compared them to one another. Participants were randomized to either:

Arm A: A maintenance regimen of Bevacizumab

Arm B: A maintenance regimen of Pemetrexed

Arm C: A maintenance regimen Bevacizumab + Pemetrexed

Who participated?

- Patients with confirmed NSCLC ages 18 years and older
- The study ran from October 2010 through August 2021
- From sites across the US, including Duke, 1,516 people participated
- The participants were between 29-87 years of age, 43% were female, and 57 % were male.
- Participants were nearly evenly randomized to the three treatments: ARM A: 287, ARM B: 294, and ARM C:293

What did we find out?

- Bevacizumab or Pemetrexed alone (Arms A + B) both proved to be effective as maintenance therapy in NSCLC.
- It was shown that the combination of bevacizumab and pemetrexed cannot be recommended (Arm C). The combined therapy did not show a survival benefit greater than the solo drugs, while also having a higher toxicity, or harmful effects, than the drugs on their own.
- Results were published in the [Journal of Clinical Oncology](#) and are posted on [ClinicalTrials.gov](#) Please let us know if you are interested in receiving a copy of the article if you are unable to access it!



What Happens Next?

Your involvement played a crucial role in advancing our understanding in NSCLC treatment.

The data we collected from participants like yourself contributes to a larger body of knowledge and aids in the progress of scientific research.

Your dedication and contribution are sincerely appreciated!

If you are interested in learning more, please call us at (919) 684-1573 or email us at debra.shoemaker@duke.edu